Introduction
Materials and methods
Samples
Genomic array preparation and data processing
CNV and statistical analysis
Validation of CNV results
Results
Array resolution and CNV detection
CNV Count | CNV Size (Kb) | ||||||
---|---|---|---|---|---|---|---|
Total CNVs per group | Median CNVs per sample | Mean CNVs per sample | Total CNV affected genome per group | Mean total CNV affected genome per sample | Mean size of a CNV | ||
Patients
| 129 | 310 | 2 | 2.40 | 29273.63 | 226.93 | 76.22 |
Controls
| 40 | 104 | 2 | 2.60 | 11820.75 | 295.52 | 106.57 |
p
| - | - | - |
0.75
| - |
0.30
|
0.07
|
Occurrence and distribution of CNVs in fBC patients
Type | Chr | Start (bp)* | End (bp)* | Size (Kb) | Probes |
---|---|---|---|---|---|
2 CNV gains
| |||||
Gain
| 2 | 13,119,088 | 13,199,687 | 80.6 | 48 |
Gain
| 2 | 13,135,013 | 13,199,687 | 64.7 | 43 |
Gain
| 2 | 82,055,473 | 82,163,764 | 108.3 | 85 |
Gain
| 2 | 82,056,404 | 82,168,370 | 112.0 | 89 |
Gain
| 3 | 958,296 | 1,012,953 | 54.7 | 33 |
Gain
| 3 | 975,908 | 1,032,700 | 56.8 | 29 |
Gain
| 6 | 27,738,385 | 27,764,062 | 25.7 | 26 |
Gain
| 6 | 27,742,403 | 27,770,374 | 28.0 | 24 |
Gain
| 15 | 79,783,294 | 79,876,946 | 93.7 | 77 |
Gain
| 15 | 79,795,446 | 79,876,343 | 80.9 | 70 |
Gain
| 17 | 21,503,478 | 21,648,413 | 144.9 | 25 |
Gain
| 17 | 21,503,478 | 21,650,626 | 147.2 | 26 |
3 CNV gains
| |||||
Gain
| 4 | 25,672,202 | 25,703,024 | 30.8 | 31 |
Gain
| 4 | 25,678,621 | 25,710,178 | 31.6 | 32 |
Gain
| 4 | 25,680,434 | 25,710,412 | 30.0 | 31 |
Gain
| 5 | 59,749,693 | 59,807,906 | 58.2 | 51 |
Gain
| 5 | 59,749,693 | 59,807,906 | 58.2 | 51 |
Gain
| 5 | 59,749,693 | 59,810,944 | 61.3 | 52 |
Gain
| 19 | 36,911,234 | 36,939,557 | 28.3 | 36 |
Gain
| 19 | 36,918,927 | 36,940,929 | 22.0 | 32 |
Gain
| 19 | 36,918,927 | 36,944,555 | 25.6 | 36 |
2 CNV losses
| |||||
Loss
| 11 | 95,844,428 | 95,917,476 | 73.1 | 54 |
Loss
| 11 | 95,844,428 | 95,917,476 | 73.1 | 54 |
Loss
| 14 | 44,229,915 | 44,294,996 | 65.1 | 53 |
Loss
| 14 | 44,229,915 | 44,294,996 | 65.1 | 53 |
Loss
| 17 | 19,439,549 | 19,476,055 | 36.5 | 28 |
Loss
| 17 | 19,439,549 | 19,476,055 | 36.5 | 28 |
Loss
| 18 | 1,714,779 | 1,828,901 | 114.1 | 109 |
Loss
| 18 | 1,714,779 | 1,828,901 | 114.1 | 109 |
4 CNV losses
| |||||
Loss
| 3 | 166,523,809 | 166,565,186 | 41.4 | 39 |
Loss
| 3 | 166,523,809 | 166,565,186 | 41.4 | 39 |
Loss
| 3 | 166,523,809 | 166,566,558 | 42.8 | 40 |
Loss
| 3 | 166,525,250 | 166,565,186 | 39.9 | 38 |
Loss
| 18 | 1,894,368 | 1,974,284 | 79.9 | 63 |
Loss
| 18 | 1,894,368 | 1,974,284 | 79.9 | 63 |
Loss
| 18 | 1,894,368 | 1,974,284 | 79.9 | 63 |
Loss
| 18 | 1,894,368 | 1,974,284 | 79.9 | 63 |
2 CNV gain and loss
| |||||
Gain
| 4 | 160,917,340 | 161,068,954 | 151.6 | 119 |
Loss
| 4 | 160,983,513 | 161,011,918 | 28.4 | 29 |
Number of Patients | Gene | Loci | |
---|---|---|---|
Gains
| 2 |
B2M
| 15q21.1 |
2 |
DSCAM
| 21q22.2 | |
2 |
G0S2
| 1q32.2 | |
2 |
GNG2
| 14q22.1 | |
2 |
GPR98
| 5q14.3 | |
2 |
IL8
| 4q13.3 | |
2 |
LAMB3
| 1q32.2 | |
2 |
LIMS1
| 2q13 | |
2 |
NBN
| 8q21.3 | |
2 |
TAGAP
| 6q25.3 | |
2 |
TRIM69
| 15q21.1 | |
Both
| 2 |
CNTN4
| 3p26.3 |
2 |
IMMP2L
| 7q31.1 | |
2 |
WWOX
| 16q23.1 | |
Losses
| 2 |
ACYP2
| 2p16.2 |
2 |
PCDH9
| 13q21.32 | |
2 |
SPINT4
| 20q13.12 | |
2 |
TSPYL6
| 2p16.2 | |
2 |
VAV3
| 1p13.3 | |
3 |
PIK3R5
| 17p13.1 | |
3 |
POU2F3
| 11q23.3 | |
4 |
ARHGEF12
| 11q23.3 | |
4 |
TMEM136
| 11q23.3 | |
5 |
NAMPT
| 7q22.2 |
Rare CNVs in fBC patients
Genes | Dx | Type | Chr | Start (bp) | End (bp) | Size (Kb) |
---|---|---|---|---|---|---|
FHIT
| 22 | Loss | 3 | 60,494,885 | 60,632,282 | 137.4 |
CARD11
| 37 | Gain | 7 | 2,946,394 | 2,996,375 | 50 |
FAM135B
| 38 | Gain | 8 | 139,259,837 | 139,306,535 | 46.7 |
ARHGEF12
| 51 | Gain | 11 | 119,697,081 | 119,723,342 | 26.3 |
TSHR
| ~49 | Gain | 14 | 80,659,512 | 80,669,166 | 9.7 |
MLLT11
| 46 | Gain | 1 | 149,289,549 | 149307059 | 17.5 |
CPD
| Gain | 17 | 25,700,671 | 25,756,973 | 56.3 | |
RHOH
| 28 | Gain | 4 | 39,864,888 | 39,888,181 | 23.3 |
ARHGAP26
| Gain | 5 | 142,147,309 | 142,174,652 | 27.3 | |
PTK2B
| Gain | 8 | 27,237,115 | 27,333,842 | 96.7 |
Genomic changes involving BC susceptibility genes or the recently identified BC susceptibility loci
Genes | Type | Chr | Start (bp) | End (bp) | Size (Kb) | |
---|---|---|---|---|---|---|
Patients
|
RPA3
| Gain | 7 | 7,670,435 | 7,697,631 | 27.2 |
NBN
| Gain | 8 | 91,048,149 | 91,070,004 | 21.9 | |
NBN
| Gain | 8 | 91,050,795 | 91,088,236 | 37.4 | |
55.7 Kb upstream MRE11A
| Gain | 11 | 93,922,391 | 93,960,356 | 38.0 | |
89.2 Kb upstream CYP19A1
| Gain | 15 | 49,507,272 | 49,579,058 | 71.8 | |
Control
| 52.6 Kb downstream NBN
| Loss | 8 | 90,913,791 | 90,962,106 | 48.3 |
Chr | Start (bp) | End (bp) | Size (Kb) | Gene | Probes | DGV |
---|---|---|---|---|---|---|
16
| 76,684,338 | 76,929,109 | 244.8 |
WWOX
| 222 | Reported |
16
| 76,947,909 | 77,009,160 | 61.3 |
WWOX
| 69 | Reported |
3
| 60,494,885 | 60,632,282 | 137.4 |
FHIT
| 158 |